TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28948137

Group type: EXPERIMENTAL
Intervention: Evidence-based intervention to promote colorectal cancer (CRC) screening; specific details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation strategies for the evidence-based intervention; specific details on dosage and duration not available.
Number of subjects: 0
Study: 28948207

Group type: EXPERIMENTAL
Intervention: Atherosclerotic CVD
Number of subjects: 32095

Group type: COMPARATOR
Intervention: Non-atherosclerotic CVD
Number of subjects: 32095

Group type: EXPERIMENTAL
Intervention: Atherosclerotic CVD (plural presence)
Number of subjects: 32095

Group type: EXPERIMENTAL
Intervention: Atherosclerotic CVD (singular presence)
Number of subjects: 32095

Group type: EXPERIMENTAL
Intervention: Overall mortality (Atherosclerotic CVD)
Number of subjects: 32095

Group type: COMPARATOR
Intervention: Overall mortality (Non-atherosclerotic CVD)
Number of subjects: 32095
Study: 28948656

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 7016

Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 7016

Group type: EXPERIMENTAL
Intervention: Combination of Aliskiren and Enalapril
Number of subjects: 7016
Study: 28950146

Group type: EXPERIMENTAL
Intervention: Buparlisib 80 mg/d + Lapatinib 1000 mg/d
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Buparlisib 40, 60, or 80 mg + Lapatinib 750, 1000, or 1250 mg
Number of subjects: 24
Study: 28950288

Group type: EXPERIMENTAL
Intervention: selumetinib 50 or 75 mg plus gemcitabine/cisplatin (n=10)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: selumetinib 50 mg plus gemcitabine/carboplatin (n=9)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: selumetinib 100 mg plus pemetrexed/carboplatin (n=21)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: selumetinib 75 mg plus pemetrexed/cisplatin (n=15)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: selumetinib (various doses) plus chemotherapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: selumetinib plus chemotherapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: selumetinib 75 mg BID with standard doses of pemetrexed/carboplatin or pemetrexed/cisplatin
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: selumetinib plus gemcitabine-containing regimens
Number of subjects: 55
Study: 28950290

Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 4996

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 4996
Study: 28950298

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg i.v. every 3 weeks until loss of clinical benefit
Number of subjects: 220

Group type: COMPARATOR
Intervention: Other systemic therapy
Number of subjects: 220

Group type: COMPARATOR
Intervention: No further systemic therapy
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 220
Study: 28950309

Group type: COMPARATOR
Intervention: Hospitals without troponin testing
Number of subjects: 15416

Group type: COMPARATOR
Intervention: Hospitals with ≥ 75% troponin use
Number of subjects: 15416

Group type: EXPERIMENTAL
Intervention: Troponin use in 2011
Number of subjects: 15416

Group type: EXPERIMENTAL
Intervention: Admissions for NSTEMI
Number of subjects: 15416
Study: 28950327

Group type: EXPERIMENTAL
Intervention: ICG-fluorescent imaging
Number of subjects: 36
Study: 28950338

Group type: EXPERIMENTAL
Intervention: Afatinib (pan HER-family kinase inhibitor)
Number of subjects: 2
Study: 28950344

Group type: EXPERIMENTAL
Intervention: Retrospective cohort (n=5069)
Number of subjects: 10570

Group type: COMPARATOR
Intervention: Prospective cohort (n=5501)
Number of subjects: 10570
Study: 28950372

Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg orally twice daily
Number of subjects: 28
Study: 28950424

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28950719

Group type: EXPERIMENTAL
Intervention: Prolonged prothrombin time (PT) with normal thromboelastometry results
Number of subjects: 76
Study: 28950783

Group type: EXPERIMENTAL
Intervention: Phoenix Atherectomy System
Number of subjects: 128
Study: 28950889

Group type: EXPERIMENTAL
Intervention: Lower urinary tract symptoms (LUTS)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Bowel symptoms
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Sexual symptoms
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Co-existence of urinary and bowel or sexual symptoms
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Late-onset FRDA
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Disease duration
Number of subjects: 56
Study: 28951336

Group type: EXPERIMENTAL
Intervention: Insulin-treated patients with type 1 diabetes
Number of subjects: 7289

Group type: EXPERIMENTAL
Intervention: Insulin-treated patients with type 2 diabetes
Number of subjects: 7289
Study: 28951352

Group type: COMPARATOR
Intervention: Simultaneous attention to two objects differing in features (face and house)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simultaneous attention to two circular arcs differing in locations
Number of subjects: 0
Study: 28951388

Group type: EXPERIMENTAL
Intervention: Retinal Microperimetry
Number of subjects: 0
Study: 28951417

Group type: EXPERIMENTAL
Intervention: Subjective risk perception of stroke and bleeding
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Patients' judgement of their own knowledge of AF
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Follow-up events
Number of subjects: 91
Study: 28951660

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 64
Study: 28952131

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) program for 4 months
Number of subjects: 37
Study: 28952191

Group type: EXPERIMENTAL
Intervention: Oral lipid tolerance test (OLTT)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: NLRP3 (hub gene for inflammation module)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: STARD3 (hub gene for energy metabolism module)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Weighted gene coexpression networks
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Functional ontology analysis of network modules
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: G-protein coupled receptor protein signaling pathway
Number of subjects: 86
Study: 28952857

Group type: EXPERIMENTAL
Intervention: Physical activity recommendations
Number of subjects: 297

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 297
Study: 28952881

Group type: EXPERIMENTAL
Intervention: Specialised palliative care intervention integrated with standard oncological care
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard oncological care
Number of subjects: 44
Study: 28952889

Group type: EXPERIMENTAL
Intervention: Incarcerated decedents
Number of subjects: 745

Group type: COMPARATOR
Intervention: Non-incarcerated decedents
Number of subjects: 745
Study: 28953554

Group type: EXPERIMENTAL
Intervention: Tumor clearance <1.0 mm
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Tumor clearance <1.5 mm
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: R1 <1.0 mm for the SMA-margin
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: R1-0 mm posterior-margin for the NAT group
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: R0-resection rates
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 147
Study: 28954004

Group type: EXPERIMENTAL
Intervention: Arterial hemoglobin oxygen saturation
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lactate level
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Glasgow Coma Scale score
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Infused crystalloid volume
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Presence of traumatic brain injury
Number of subjects: 200
Study: 28954285

Group type: EXPERIMENTAL
Intervention: Proton-based stereotactic body radiation therapy (SBRT) with a median dose of 40 GyE (range = 30-50 GyE) in five fractions.
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Proton-based SBRT for tumors with KRAS mutation.
Number of subjects: 89
Study: 28954716

Group type: COMPARATOR
Intervention: Telephone intervention (n=13)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Internet intervention (n=24)
Number of subjects: 37
Study: 28954781

Group type: EXPERIMENTAL
Intervention: Network analysis approach for understanding ECOPD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 28955494

Group type: EXPERIMENTAL
Intervention: ADA + 2.5, 5, 10 or 20 mg/week MTX for 26 weeks (CONCERTO)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: ADA + 7.5 or 20 mg/week MTX for 24 weeks (MUSICA)
Number of subjects: 704
Study: 28955496

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) enthesis abnormalities
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) scores
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: US structural scores
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: PDUS scores
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: US enthesophytes
Number of subjects: 402
Study: 28955499

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 0
Study: 28955501

Group type: EXPERIMENTAL
Intervention: Coronary CT angiography (CCTA)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Risk prediction model
Number of subjects: 86
Study: 28956082

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 24
Study: 28956281

Group type: EXPERIMENTAL
Intervention: Autoinjector for self-administration of subcutaneous belimumab
Number of subjects: 43
Study: 28956335

Group type: EXPERIMENTAL
Intervention: PDE9 inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PDE inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO)/cGMP pathway and NMDA receptor signaling
Number of subjects: 0
Study: 28956734

Group type: EXPERIMENTAL
Intervention: Perfusion CT
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Perfusion MR
Number of subjects: 92
Study: 28957445

Group type: EXPERIMENTAL
Intervention: Prediction model for detection of ≥1 adenoma
Number of subjects: 19968

Group type: EXPERIMENTAL
Intervention: Independent predictors for detection of ≥1 adenoma
Number of subjects: 19968

Group type: EXPERIMENTAL
Intervention: Model's discriminative ability
Number of subjects: 19968

Group type: EXPERIMENTAL
Intervention: Observed vs predicted ADR
Number of subjects: 19968
Study: 28958347

Group type: EXPERIMENTAL
Intervention: GDF-15 levels
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: GDF-15 therapy
Number of subjects: 910
Study: 28958801

Group type: EXPERIMENTAL
Intervention: Predictive models using genetic data and baseline molecular and clinical variables from patients with Parkinson's disease
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Model ensemble
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Machine-learning approaches
Number of subjects: 429
Study: 28959122

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed wheat-based cereals (pHC)
Number of subjects: 9
Study: 28959463

Group type: EXPERIMENTAL
Intervention: Solitaire thrombectomy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Medical group (control)
Number of subjects: 300
Study: 28959486

Group type: EXPERIMENTAL
Intervention: Carotid artery MRI of bilateral carotid arteries and routine brain MRI with standardised protocols
Number of subjects: 1000
Study: 28959500

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin combined with R-GDP
Number of subjects: 0
Study: 28959913

Group type: EXPERIMENTAL
Intervention: Somatostatin analog octreotide + telotristat ethyl (SSA + TE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Somatostatin analog octreotide (SSA)
Number of subjects: 0
Study: 28960029

Group type: EXPERIMENTAL
Intervention: Submillisievert chest computed tomography (CT) scan (effective dose, 0.19-0.25 millisievert)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Submillisievert chest computed tomography (CT) scan
Number of subjects: 6
Study: 28960096

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSCs) at doses of 0.3, 1.0, and 3.0 million cells/kg (up to 250 million cells)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control cohort (21 participants)
Number of subjects: 30
Study: 28960673

Group type: EXPERIMENTAL
Intervention: Screening for heart transplantation (HTx) and left ventricular assist systems (LVAS)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Screening intervention
Number of subjects: 99
Study: 28961153

Group type: EXPERIMENTAL
Intervention: Newly developed transportation measure
Number of subjects: 244
Study: 28961812

Group type: EXPERIMENTAL
Intervention: Meropenem 2000 mg/6 h by intermittent (30 min) or prolonged (3 h) infusion for A. baumannii
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Meropenem 6000 mg/day by continuous infusion for A. baumannii
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Meropenem 2000 mg/8 h or 1000 mg/6 h for P. aeruginosa
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Meropenem 1000 mg/8 h for patients with CLCR ≤ 100 mL/min
Number of subjects: 50
Study: 28961847

Group type: EXPERIMENTAL
Intervention: Image-guided multiregion transperineal biopsy
Number of subjects: 49
Study: 28962047

Group type: EXPERIMENTAL
Intervention: 2 mg Dexamethasone Suppression Test (DST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 mg Dexamethasone Suppression Test (DST)
Number of subjects: 0
Study: 28962551

Group type: EXPERIMENTAL
Intervention: Angiopoietin-like protein 2 (Angptl2) combined index (ACI)
Number of subjects: 460

Group type: COMPARATOR
Intervention: APRI
Number of subjects: 460

Group type: COMPARATOR
Intervention: FIB-4
Number of subjects: 460

Group type: COMPARATOR
Intervention: Hui model
Number of subjects: 460

Group type: COMPARATOR
Intervention: Forn's index
Number of subjects: 460
Study: 28962909

Group type: EXPERIMENTAL
Intervention: Kyphoplasty and intraoperative radiotherapy (Kypho-IORT)
Number of subjects: 61
Study: 28963284

Group type: EXPERIMENTAL
Intervention: The Newborn Behavioral Observation (NBO) - three sessions within the first 4 weeks postdelivery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200
Study: 28963288

Group type: EXPERIMENTAL
Intervention: Adiposity measures (BMI, WHtR, CUN-BAE, BRI)
Number of subjects: 2354

Group type: EXPERIMENTAL
Intervention: CAVI
Number of subjects: 2354

Group type: EXPERIMENTAL
Intervention: baPWV
Number of subjects: 2354

Group type: EXPERIMENTAL
Intervention: Adiposity measures
Number of subjects: 2354
Study: 28963297

Group type: EXPERIMENTAL
Intervention: Clinical and haemodynamic variables obtained by physical examination and critical care ultrasound (CCUS)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: CCUS images of sufficient quality
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Focused training for obtaining specific CCUS images
Number of subjects: 704
Study: 28963316

Group type: EXPERIMENTAL
Intervention: Donation-specific interventions
Number of subjects: 650

Group type: COMPARATOR
Intervention: Current practices
Number of subjects: 650

Group type: COMPARATOR
Intervention: Research consent model
Number of subjects: 650

Group type: COMPARATOR
Intervention: Participation of academic and community hospitals and ODOs
Number of subjects: 650

Group type: COMPARATOR
Intervention: Accessibility of recipient data
Number of subjects: 650
Study: 28963781

Group type: EXPERIMENTAL
Intervention: Antiviral therapy (356 patients total)
Number of subjects: 1576

Group type: EXPERIMENTAL
Intervention: Interferon-a (264 patients)
Number of subjects: 1576

Group type: EXPERIMENTAL
Intervention: HBV-Nucs only (92 patients)
Number of subjects: 1576

Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 1576
Study: 28964314

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg rocuronium
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg rocuronium
Number of subjects: 75

Group type: COMPARATOR
Intervention: Normal saline (S Group)
Number of subjects: 75
Study: 28964326

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-diabetic men
Number of subjects: 21
Study: 28964701

Group type: EXPERIMENTAL
Intervention: REP 2139 and pegylated interferon alfa-2a
Number of subjects: 12
Study: 28964736

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg Q2W
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q2W
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Alirocumab in LDLR-negative heterozygotes
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Alirocumab in APOB-defective heterozygotes
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Alirocumab in PCSK9 heterozygotes
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Alirocumab in patients with no identified mutations
Number of subjects: 1191

Group type: COMPARATOR
Intervention: Alirocumab
Number of subjects: 1191
Study: 28964826

Group type: EXPERIMENTAL
Intervention: High-resistance concentric-eccentric training (HHH) 3d/week
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-resistance training (HH) 2d/week
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Mixed model (HLH) 3d/week consisting of H training 2d/week and 1 bout of low-resistance, high-velocity, concentric only training
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Mixed model (HL) 2d/week consisting of H training 1d/week and L training 1d/week
Number of subjects: 64
Study: 28965093

Group type: EXPERIMENTAL
Intervention: Preventive treatment for hypertension (antihypertensive medication)
Number of subjects: 10003

Group type: EXPERIMENTAL
Intervention: Preventive treatment for dyslipidaemia (statin)
Number of subjects: 10003

Group type: EXPERIMENTAL
Intervention: Preventive treatment for diabetes (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker)
Number of subjects: 10003

Group type: EXPERIMENTAL
Intervention: Lifestyle factors (sedentary behavior)
Number of subjects: 10003

Group type: EXPERIMENTAL
Intervention: Lifestyle factors (smoking)
Number of subjects: 10003

Group type: EXPERIMENTAL
Intervention: Lifestyle factors (obesity)
Number of subjects: 10003

Group type: EXPERIMENTAL
Intervention: Treatment gap in dyslipidaemia
Number of subjects: 10003
Study: 28965106

Group type: EXPERIMENTAL
Intervention: WEB treatment
Number of subjects: 168
Study: 28965185

Group type: EXPERIMENTAL
Intervention: Erdafitinib 2, 4, or 6 mg daily dosing schedule
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Erdafitinib 10 mg or 12 mg intermittent dosing schedule
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Erdafitinib (all doses)
Number of subjects: 19
Study: 28965778

Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28966645

Group type: EXPERIMENTAL
Intervention: Nocturnal concentrations of melatonin, GABA, and total antioxidants in peripheral blood (insomnia group)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nocturnal concentrations of melatonin, GABA, and total antioxidants in peripheral blood (non-insomnia group)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Severity of stroke (insomnia group)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index, Insomnia Severity Index, Epworth Sleepiness Scale, Fatigue Severity Scale, Morningness-Eveningness Questionnaire (Chinese version), National Institute of Health Stroke Scale (insomnia group)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Pittsburgh Sleep Quality Index, Insomnia Severity Index, Epworth Sleepiness Scale, Fatigue Severity Scale, Morningness-Eveningness Questionnaire (Chinese version), National Institute of Health Stroke Scale (non-insomnia group)
Number of subjects: 75
Study: 28967387

Group type: EXPERIMENTAL
Intervention: Bacteriologic criterion of ≥10,000 colony forming units/mL of a single organism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Properly collected urine
Number of subjects: 0
Study: 28968874

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted influenza A/California/7/2009 (pH1N1) vaccine
Number of subjects: 92
Study: 28968971

Group type: EXPERIMENTAL
Intervention: Novel surgical method for intraoperative precise sentinel lymph node biopsy (SLNB) guided by lymphatic drainage
Number of subjects: 125
Study: 28969597

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation
Number of subjects: 12
Study: 28970100

Group type: EXPERIMENTAL
Intervention: Intensive training with functional electrical stimulation for 1 hour per day, 5 days per week for 8 weeks.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care plus three 15-minute sessions per week of one-to-one hand therapy without functional electrical stimulation.
Number of subjects: 70
Study: 28970161

Group type: EXPERIMENTAL
Intervention: Combined therapy with colistin (9 million UI/day) and tigecycline (100 mg/day)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Monotherapy with colistin (9 million UI/day)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Combined therapy with colistin and tigecycline
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Empirical therapy with colistin
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Renal dysfunction before treatment
Number of subjects: 118
Study: 28970192

Group type: EXPERIMENTAL
Intervention: Computer-based stress management with minimal contact (iCBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stress management with face-to-face interviews (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait list control group (WLC)
Number of subjects: 0
Study: 28970202

Group type: EXPERIMENTAL
Intervention: Postprandial resistance exercise (M-Ex)
Number of subjects: 11

Group type: COMPARATOR
Intervention: No exercise (NoEx)
Number of subjects: 11
Study: 28970332

Group type: EXPERIMENTAL
Intervention: Visual assessments of fundic accommodation by trained readers (nuclear medicine and radiology physicians) during solid-meal gastric emptying scintigraphy (GES)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Software developed to quantify intragastric meal distribution (IMD) during GES
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gastric emptying measurements
Number of subjects: 0